Endocrine therapies that inhibit estrogen receptor (ER)-a signaling are the most common and effective treatment for ER-a-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The aim of this study was to elucidate the mechanisms by which downregulation of CDK10 expression confers resistance to tamoxifen in breast cancer. Here, we show that peptidyl-prolyl isomerase Pin1 downregulates CDK10 protein as a result of its interaction with and ubiquitination of CDK10, thereby affecting CDK10-dependent Raf-1 phosphorylation (S338). Pin1 -/-mouse embryonic fibroblasts (MEFs) show higher CDK10 expression than Pin1 þ / þ MEFs, whereas CDK10 protein was downregulated in the rescued Pin1 -/-MEFs after reexpression of Pin1. Pin1 silencing in SKBR-3 and MCF7 cells increased the CDK10 expression. In human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 cells, immunohistochemical staining and immunoblotting analysis shows an inverse correlation between the expression of CDK10 and the degree of tamoxifen resistance. There was also a positive correlation between the high level of P-Raf-1 (Ser338) and Pin1 in human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 (TAMR-MCF7) cells. Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively. On the basis of these findings, we suggest that the Pin1-mediated CDK10 ubiquitination is a major regulator of tamoxifen-resistant breast cancer cell growth and survival.
Introduction
Approximately 70% of all breast cancers are dependent on estrogen and a functional estrogen receptor a (ER-a) for their growth (Deroo and Korach, 2006) . Hence, ERpositive (ER þ ) breast cancer is usually treated with hormone reduction or anti-estrogen (Ali and Coombes, 2002) . Tamoxifen, which is historically the most frequently used anti-estrogen, has been shown to reduce breast cancer recurrence rates and mortality in woman with ER þ cancer (EBCTCG, 2005) . Unfortunately, only half of the recurrences in ER þ breast tumors respond to tamoxifen, whereas the other half show resistance (Clarke et al., 2003) . Several molecules, signal transduction pathways, and mechanisms have been implicated in acquired anti-estrogen resistance, including downregulation of ER expression and/or function (Le Goff et al., 1994; Giacinti et al., 2006) , increased cellular responses to the partial agonist activities of tamoxifen (Riggs and Hartmann, 2003) , overexpression of HER-2 (Pietras et al., 1995) , epidermal growth factor receptor or SRC-1 (Shang and Brown, 2002) , and stabilization of the interaction between ER-a and SRC-1 by cyclin D1 (Zwijsen et al., 1997) and cyclin A-CDK2 (Trowbridge et al., 1997) . Although many of these studies have been highly informative, the underlying molecular mechanism by which reduction of CDK10 expression during chemoendocrine treatment occasionally causes resistance to tamoxifen remains unclear.
Cell cycle progression is tightly controlled by the activity of cyclin-dependent kinases (CDKs) (Norbury and Nurse, 1992) . Ten CDKs (CDK1-CDK10) are currently known, of which only CDK1, 2, 3, 4 and 6 intervene directly in the cell cycle, whereas CDK7 has an indirect role as an activator of these CDKs (Morgan, 1997) . CDK10, previously referred to as PISSLRE, is a member of the CDC2 family of kinases and has been implicated in the regulation of and cell cycle progression in G2/M and cellular proliferation (Li et al., 1995) . CDK10 was originally identified based on its homology to CDC2 and bears the hallmarks common to CDKs (Brambilla and Draetta, 1994) . Recently, it was reported that CDK10 silencing increases the activity of the transcription factor ETS2 on the promoter of the RAF1 gene, resulting in MAPK pathway activation and loss of tumor cell reliance upon estrogen signaling (Iorns et al., 2008) . These findings elucidate the molecular mechanism of ER regulation and indicate that further investigation of the role and therapeutic potential of CDK10 in the treatment of endocrineresistant breast cancers is needed.
Pin1 is a peptidyl-prolyl isomerase that binds and isomerizes specific phosphorylated serine or threonine residues that precede proline (pSer/Thr-Pro) in certain proteins (Lu et al., 1996) . These Pin1-induced conformational changes have profound effects on the function of many Pin1 substrates by modulating their activity levels, phosphorylation status, protein-protein interactions, subcellular localization and protein stability (Lu et al., 1996; Yaffe et al., 1997) . Pin1 has been shown to be involved in the regulation of many cellular events, such as cell cycle progression, transcriptional regulation, and cell proliferation (Lu et al., 2002; Ryo et al., 2003) . Furthermore, Pin1 is highly overexpressed in many human cancers, and high Pin1 levels correlate with poor prognosis in breast cancer (Wulf et al., 2001; Lu, 2003) . Recently, our group reported that Pin1 has been shown to induce the expression of LC-3 to facilitate the progression of tamoxifen resistance in breast cancer (Namgoong et al., 2010) . However, it is not known whether Pin1 regulates the stability of CDK10, resulting in acquisition of tamoxifen resistance. Here we show that CDK10 is tightly regulated by Pin1-mediated ubiquitination and suggest that downregulation of these mechanisms may enhance tamoxifen sensitivity in human breast cancer.
Results

Pin1 downregulates expression of CDK10 protein in breast cancer cells
To explore the effects of Pin1 on CDK10 protein expression, Pin1
and Pin1 -/-mouse embryonic fibroblasts (MEFs) were cultured under normal culture conditions and immunoblotting was done with the antibody against CDK10. Increased CDK10 expression was observed in Pin1 -/-MEFs compared with Pin1
MEFs, whereas cyclin D1 protein was decreased in Pin1 -/-MEFs (Figure 1a , left). To ensure that this decreased CDK10 level in Pin1 -/-MEFs was due to the loss of Pin1, Pin1 -/-MEFs were rescued by reexpression of Pin1. The results showed that CDK10 level was downregulated in rescued Pin1 -/-MEFs, whereas cyclin D1 level was increased in rescued Pin1 -/-MEFs ( Figure 1a , right). To further confirm that Pin1 silencing increases CDK10 level, siRNA-Pin1 was transfected into SKBR-3 and MCF7 cells. Pin1 silencing increased CDK10 expression in both cells ( Figure 1b) . Next, various doses of pcDNA4-Xpress-Pin1 were transfected into MCF7 cells and the cells were incubated for 48 h. The overexpression of Pin1 downregulated CDK10 protein but increased cyclin D1 ( Figure 1c ). As previous evidence indicates that Pin1 WW domain, specifically Ser16, regulates its ability to function as a pSer/Thr-Probinding module (Finn and Lu, 2008) , we asked whether the mutant of Pin1, Pin1-S16A, has a different effect on the CDK10 protein expression. The results showed that CDK10 level was decreased in Pin1-WT-transfected MCF7 cells, but not in Pin1-S16A-transfected MCF7 cells ( Figure 1d) .
Next, endogenous Pin1 expression was induced with the addition of FBS or IGF in MCF7 cells, respectively. The expression of Pin1 and cyclin D1 were increased by stimulation of FBS or IGF time-dependently, whereas FBS or IGF progressively downregulated CDK10 levels, indicating that endogenous Pin1 might affect CDK10 expression (Figure 1e ). Given the close correlation between Pin1 and CDK10 in protein expression, we then analyzed mRNA levels of cdk10 after overexpression or knockdown of Pin1 in MCF7 cells, respectively. Semi-quantitative RT-PCR results showed that the cdk10 mRNA level was not affected by overexpression or knockdown of Pin1 in MCF7 cells (Figure 1f ), suggesting that Pin1 may affect the stability of CDK10.
Pin1 interacts with CDK10 in vitro and ex vivo M2H assay was performed to examine whether Pin1 could physically interact with CDK10. As shown in Figure 2a , Pin1 most strongly bound with CDK10 compared with CDK1, CDK3, CDK5 and CDK7 in vitro. To further confirm the interaction between Pin1 and CDK10, HEK293 cells were cotransfected with pcDNA-Xpress-Pin1 and pBIDN-GAL4-CDK10. Reciprocal immunoprecipitation/immunoblotting using anti-Xpress and anti-GAL4 antibodies showed that exogenously expressed Pin1 interacted with GAL4-CDK10 in vitro (Figure 2b ). To determine the region of Pin1 that was responsible for its interaction with CDK10, pBIND-Pin1-WT, -WW and -PPIase plasmids were cotransfected with pACT-CDK10, and the interactions were examined by M2H assay. The Pin1-binding site on CDK10 encompasses amino acids 1-44 in the WW domain ( Figure 2c ). As the previous result indicated that the Ser16 motif of Pin1 is a critical factor for CDK10 expression (Figure 1d ), we examined whether Pin1-S16A affects its interaction with CDK10. Immunoprecipitation/immunoblotting analyses revealed that CDK10 directly bound with Pin1-WT, but not its S16A mutant, in vitro ( Figure 2d) .
As Pin1 is known to target Ser/Thr-Pro motifs, when the serine or theronine preceding the proline is phosphorylated (Finn and Lu, 2008) , we examined whether CDK10 could be phosphorylated at the Ser-or Thr-Pro motif. The result showed that FBS stimulation induced the phosphorylation of CDK10 at a Thr-Pro residue, suggesting that phospho-Thr-Pro motif in CDK10 may be necessary for Pin1 binding (Figure 2e ). There are three Thr-Pro motifs in human CDK10 protein, Thr133, Thr196 and Thr257, whereas no any Ser-Pro motifs. We mutated each of three Thr residues followed a Pro in CDK10 to Ala and investigated the ability of this non-phosphorylated mutant to bind to Pin1. The results showed that mutation of Thr133 site in CDK10 led to a significant loss of binding between CDK10 and Pin1 (Figure 2f ). To further define whether the interaction between CDK10 and Pin1 was dependent on CDK10 phosphorylation, whole-cell lysates from cells transfected with GAL4-CDK10 were treated with increasing amounts of phosphatase and analyzed for their ability to bind to GST-Pin1 in a GST pull-down experiment. As expected, the treatment of phosphatase resulted in decreased interaction between CDK10 and Pin1 ( Figure 2g ). We next examined whether the interaction of CDK10 and Pin1 was detectable at the endogenous level. MCF7 cells were starved, stimulated with FBS and subjected to immunoprecipitation with anti-CDK10 or anti-Pin1 antibody, respectively. Endogenous CDK10 interacted with Pin1 in FBS-stimulated cells, but not in the un-stimulated cells (Figure 2h ), suggesting that Pin1 interacts with CDK10 ex vivo in a phosphorylationdependent manner.
Pin1 leads to decreased CDK10 levels through its ubiquitination To examine whether CDK10 is appropriately degraded in the presence of Pin1, Pin1 þ / þ and Pin1 -/-MEFs were treated with cycloheximide for various time periods. Figure 3a (top) shows that the inhibition of translation led to an 80% decrease in CDK10 protein in wild-type cells, whereas CDK10 turnover was impaired in the Pin1 -/-MEFs and indeed showed no decrease at 12 h after the addition of cycloheximide. To further examine the effect of Pin1 on CDK10 stability, Xpress-Pin1 was transfected into MCF7 cells, followed by treatment with cycloheximide time-dependently. In agreement with the result obtained in Pin1 MEFs, overexpression of Pin1 (a) pBIND-Pin1 and pACT-CDKs plasmids (CDK1, CDK3, CDK5, CDK7 and CDK10) were cotransfected along with pG5-luc plasmid into HEK293 cells. After 48 h, the firefly luciferase activity was determined in the cell lysates and normalized against renilla luciferase activity. Columns, mean of triplicate samples; bars, s.e. *Po0.05, compared with only pG5-luc-transfected cells. (b) Xpress-Pin1 and GAL4-CDK10 were cotransfected into HEK293 cells. After 48 h, immunoprecipitation (IP) was performed to precipitate CDK10 (left) and Pin1 (right), and immunoblotting (IB) analysis was performed using antibodies against Xpress-Pin1 (left) and GAL4-CDK10 (right), respectively. Normal IgG antibody from a goat was used as a negative control for immunoprecipitation. (c) Top, schematic diagram of full-length (1-163) pBIND-Pin1 WT (Pin1-WT), WW domain (1-44) of pBIND-Pin1 (Pin1-WW) or the PPIase domain (40-163) of pBIND-Pin1 (Pin1-PPIase); bottom, the pBINDPin1-WT, -WW or -PPIase plasmids were cotransfected with pACT-CDK10 and pG5-luc plasmid into HEK293 cells. After 48 h, the firefly luciferase activity was determined in the cell lysates and normalized against renilla luciferase activity. Columns, mean of triplicate samples; bars, s.e. *Po0.05, compared with only pG5-luc-transfected cells. (d) GAL4-CDK10 was cotransfected with XpressPin1-WT or Xpress-Pin1-S16A plasmid, respectively. After 48 h of transfection, proteins were extracted and used for immunoprecipitation with anti-Xpress antibody; the immune complexes were analyzed by anti-GAL4 immunoblotting. (e) MCF7 cells were starved, stimulated with 10% FBS for 4 h, harvested and lysed. Immunoprecipitation was performed to precipitate phosphorylated proteins at threonine residue immediately preceding proline with anti-pThr-Pro (pT-P) antibody and CDK10 was detected by immunoblotting with anti-CDK10 antibody. (f) GAL4-CDK10-WT, -T133A, -T196A and -T257A were transfected into HEK293 cells, respectively. After 48 h, cell lysates were subjected to GST pull-down analysis with GST or GST-Pin1 followed by immunoblotting with anti-GAL4 antibody. (g) Cell lysates derived from HEK293 cells transfected with GAL4-CDK10 were treated or untreated with calf intestine alkaline phosphatase, followed by GST pull-down analysis with GST or GST-Pin1 and immunoblotting with anti-GAL4 antibody. (h) Whole-cell lysates from MCF7 cells stimulated with 10% FBS for 4 h after starvation were immunoprecipitated with anti-Pin1 (left) or anti-CDK10 (right) antibodies, respectively. The immunopellets were separated by SDS-PAGE, and immunoblotting was performed with anti-CDK10 or anti-Pin1.
Pin1 induces CDK10 ubiquitination P Khanal et al enhanced the degradation of CDK10 by cycloheximide treatment in MCF7 cells (Figure 3a , bottom). Next, cycloheximide-treated MCF7 cells were serum-starved and then endogenous Pin1 expression was induced with the addition of 10% FBS. In contrast to increased Pin1 expression, the CDK10 level was decreased by stimulation with FBS (Figure 3b, top) . Next, we asked whether the ubiquitin-mediated proteolytic pathway is responsible for CDK10 degradation by comparing protein stability in the absence or presence of MG132 with/ without transfection of Xpress-Pin1. MG132 strikingly inhibited Pin1-mediated CDK10 degradation, suggesting involvement of the ubiquitin-mediated pathway (Figure 3b , bottom). To examine whether Pin1 mediates CDK10 ubiquitination in vitro, Pin1-WT or Pin1-S16A was cotransfected with GAL4-CDK10 and HA-ubiquitin in MCF7 cells. CDK10 was ubiquitinated in the presence of Pin1-WT, but not Pin1-S16A (Figure 3c ). Consistent with this, Pin1 silencing in MCF7 cells decreased the ubiquitination of CDK10 induced by FBS and increased its stability (Figure 3d ).
Increased Raf-1 activity in TAMR-MCF7 cells is associated with decreased CDK10 level by Pin1
To investigate the pathological relevance of the relationship between CDK10, Raf-1, P-Raf-1 (Ser338) and Pin1 in tamoxifen-resistant breast cancers, we analyzed these proteins in eight human non-tamoxifen-resistant and four human tamoxifen-resistant breast cancer tissue samples. Immunohistochemical staining showed that overexpression of Pin1 is associated with decreased CDK10 and increased P-Raf-1 (Ser338) in human tamoxifen-resistant breast cancer samples (Po0.010, Fisher's exact test; Figure 4a ). Comparison of Pin1, CDK10 and P-Raf-1 (Ser338) levels in MCF7 and TAMR-MCF7 cells showed decreased CDK10 expression and increased Raf-1 phosphorylation (Ser338) and Pin1 expression in TAMR-MCF7 cells (Figure 4b , left). Consistent with this result, CDK10 silencing in MCF7 cells increased the phosphorylation of Raf-1 without changing Pin1 levels (Figure 4b , right), suggesting that CDK10 signaling pathway may inhibit phosphorylation of Raf-1 at Ser338. To further examine whether phosphorylation of Raf-1 is regulated by Pin1-downregulated CDK10 level, Xpress-Pin1 and siRNA-Pin1 was transfected in MCF7 and TAMR-MCF7 cells. The result showed that Pin1 overexpression in MCF7 cells decreased the CDK10 level, but increased the Raf-1 phosphorylation. Similarly, Pin1 silencing in TAMR-MCF7 cells increased the CDK10 level and decreased the Raf-1 phosphorylation (Figure 4c ). To examine the effect of CDK10 on the phosphorylation of Raf-1, þ / þ and Pin1 -/-MEF cells were treated with cycloheximide (CHX, 100 mg/ml) for various time periods, harvested and immunoblotted; bottom, mock and Xpress-Pin1 were transfected into MCF7 cells. After 48 h, the cells were treated with CHX (100 mg/ml) for various time periods, harvested and immunoblotted. (b) Top, MCF7 cells were starved, treated with CHX (100 mg/ml) for 12 h, and then exposed to 10% FBS. Expression levels of CDK10 and Pin1 were detected. Bottom, mock and Xpress-Pin1 plasmid were transfected into MCF7 cells. After 48 h, cells were treated with MG132 (20 mM) for 24 h, harvested, and immunoblotted. Corresponding signal intensities were densitometrically determined and given below. (c) GAL4-CDK10, Xpress-Pin1-WT and Xpress-Pin1-S16A were cotransfected along with pcDNA-HA-ubiquitin into MCF7 cells. After 48 h, GAL4-CDK10 was immunoprecipitated, and immunoblotting analysis was performed using respective antibodies against anti-HA and anti-GAL4. (d) Control-siRNA and siRNA-Pin1 were cotransfected with pcDNA-HA-ubiquitin into MCF7 cells. After 48 h, cells were starved for 24 h, exposed to 10% FBS for 4 h, and harvested. Whole cell extracts were subjected to anti-CDK10 immunoprecipitation followed by anti-HA and anti-CDK10 immunoblotting.
Pin1 induces CDK10 ubiquitination P Khanal et al TAMR-MCF7 cells were transfected with GAL4-CDK10. The result showed that CDK10 overexpression in TAMR-MCF7 cells decreased the Raf-1 phosphorylation (Figure 4d, left) . Then, we assessed the possible crosstalk between Raf-1 phosphorylation and CDK10 levels through overexpression of Pin1. We found that the increased Raf-1 phosphorylation by Pin1 was inhibited by CDK10 overexpression in MCF7 cells (Figure 4d, right) . Consistent with this, CDK10 overexpression inhibited the Raf-1 phosphorylation induced by FBS (Figure 4e ).
CDK10 overexpression enhances tamoxifen-induced apoptotic signaling As Pin1 downregulates the CDK10 expression level, we next assessed the effect of tamoxifen on the cell viability of Pin1-overexpressing MCF7 cells. The results showed that MSCV-Pin1 cells were more resistant to tamoxifen than the MSCV-GFP cells (Figure 5a, top) , suggesting that downregulation of CDK10 by Pin1 may be related with the tamoxifen resistance of breast cancer. We next tested whether CDK10 overexpression could potentiate tamoxifen sensitivity in TAMR-MCF7 cells. Treatment Pin1 induces CDK10 ubiquitination P Khanal et al of 4-OHT reduced viability of TAMR-MCF7 cells by 28%, whereas CDK10 overexpression increased sensitivity to 4-OHT by 63% (Figure 5a, bottom) . We examined the effects of CDK10 overexpression on 4-OHT-induced cell death by PARP cleavage. 4-OHT induced higher cleavage of PARP after CDK10 overexpression in MCF7 and TAMR-MCF7 cells (Figure 5b ). 4-OHT-induced DNA fragmentation was also higher in CDK10-overexpressing TAMR-MCF7 cells, as measured in a TUNEL assay ( Figure 5c ). Next, we examined whether CDK10 overexpression affects the tamoxifen-induced inhibition of cologenic growth of After 48 h, the cells were starved for 24 h, exposed to 4-OHT for 24 h, harvested, lysed and immunoblotted. Corresponding signal intensities of protein were densitometrically determined and given below of each respective band. (c) Mock and GAL4-CDK10 were transfected into TAMR-MCF7 cells. After 24 h, the cells were starved, treated with 4-OHT for additional 24 h, and then DNA fragmentation induced by 4-OHT was detected. FITC, fluorescein isothiocyanate; DAPI, 4 0 ,6-diamidino-2-phenylindole. (d) Top, TAMR-MCF7 cells were transfected with mock and GAL4-CDK10, respectively, and subjected to soft agar assays in the absence or presence of 4-OHT (5 mM); bottom, average colony numbers were measured. Columns, mean of triplicate samples; bars, s.e. *Po0.05.
Pin1 induces CDK10 ubiquitination P Khanal et al
TAMR-MCF7 cells. The results showed that CDK10 overexpression in TAMR-MCF7 cells significantly increased the sensitivity to 4-OHT (Figure 5d ).
Co-treatment of 4-OHT with sorafenib enhances tamoxifen sensitivity
The increased phosphorylation of Raf-1 (Figure 4a ) in tamoxifen-resistant breast cancers supports the hypothesis that tamoxifen resistance may occur through activation of growth factor signaling through Raf (Oh et al., 2001) . Therefore, we examined whether treatment of 4-OHT with Raf-1 inhibitor, sorafenib, in combination increased tamoxifen sensitivity in TAMR-MCF7 cells. The co-treatment of sorafenib with 4-OHT significantly enhanced the tamoxifen sensitivity of TAMR-MCF7 cells in MTT assay (Figure 6a ) and flow 
Discussion
There has been a recent realization that CDK10 silencing causes resistance to tamoxifen and estrogen deprivation, resulting from MAPK pathway activation (Iorns et al., 2008) . In addition, transfection of constitutively active MEK1 or Raf-1 into MCF7 cells, which results in hyperactivation of the MAPK signaling pathway, causing a loss of ER-a-mediated gene expression, characterized by acquisition of antiestrogen resistance (El-Ashry et al., 1997). Interestingly, it was reported that Pin1 regulates SMRT and SRC-3, as downstream effectors of HER2 signaling (Yi et al., 2005; Stanya et al., 2008) , which is often increased in endocrine-resistant breast tumors and contributes to activate proliferation and/or survival and hormone resistance (Shou et al., 2004; Osborne et al., 2005) . It is thus important to understand how these versatile proteins are regulated at steady-state levels and in response to various extracellular stimuli and in turn, how these regulations may affect endocrine therapy resistance. Taken together with our increasing understanding of endocrine therapy resistance, this work highlights how Pin1 can facilitate degradation of CDK10, leading to tamoxifen resistance in breast cancer. By binding and isomerizing specific pSer/Thr-Pro bonds, Pin1 regulates the conformation and function of specific phosphorylated proteins and thus has an important role in many diverse cellular processes (Lu et al., 2002; Ryo et al., 2003) . The Pin1 WW domain, specifically Ser16, regulates its ability to function as a pSer/Thr-Pro-binding module (Finn and Lu, 2008) . Our study indicates that CDK10 interacts with WW domain of Pin1, which leads to degradation of CDK10 protein.
We show that CDK10 interaction with Pin1 can be detected both in vitro and ex vivo. Although we cannot decisively conclude that there is a direct interaction between the two proteins from our data, there are several lines of evidence that strongly suggest a direct interaction. First, our data show that the interaction is dependent on phosphorylation of CDK10 and is mediated through the WW domain of Pin1, which is known to bind pSer/Thr-Pro motifs. Second, a mutant of CDK10 with Thr-to-Ala substitution at Thr133-Pro motif couldn't bind to Pin1. Taken together, these data support the idea that Pin1 can bind CDK10 via its phosphorylated Thr133-Pro motif.
Our data further suggest that the result of the interaction between CDK10 and Pin1 is a decrease in the steady-state level of CDK10. Although CDK10 is unstable in WT MEFs and other cells expressing Pin1, it is quite stable in Pin1 À/À MEFs and could be stabilized by proteasome inhibitor, MG132. Furthermore, CDK10 protein level was decreased by stimulation with FBS, subsequent to increased Pin1 levels. It was recently reported that low levels of CDK10 were associated with methylation of the CpG island in the CDK10 promoter, which is a common transcriptional mechanism (Iorns et al., 2008) . Intriguingly, Hellen et al. showed that CDK10 is not a target for aberrant DNA methylation in breast cancer (Heller et al., 2009) . Thus, we hypothesize that post-translational modification of CDK10 may take precedence over actual levels in affecting its activity. Previous studies have indicated that Pin1 can modulate polyubiquitination and subsequent protein degradation of substrates with a short-lifetime, such as Myc, p53, p73 and b-catenin (Wulf et al., 2005) . The regulation of CDK10 stability has been further supported by our findings that CDK10 is polyubiquitinated by overexpression of Pin1. Although we cannot conclude that this ubiquitination is a direct consequence of the binding of CDK10 to Pin1, our results with mutant of Pin1 strongly support this conclusion. When Pin1 was mutated at Ser16, the Pin1 mutant couldn't bind to and promote CDK10 polyubiquitination. In addition, Pin1 knockdown suppressed CDK10 polyubiquitination induced by FBS. Taken together, these results suggest that Pin1 may promote ubiquitination-mediated CDK10 degradation through its direct interaction with CDK10.
Epidermal growth factor receptor/HER2 and its downstream Raf-1/MAPK signaling, which were barely detected in control estrogen-treated tumors, increased slightly with tamoxifen treatment and were markedly increased when tumors became resistant (Massarweh et al., 2008) . Increased Raf-1/MAPK phosphorylation or activation is associated with early relapse on adjuvant tamoxifen, suggesting that nuclear Raf-1 phosphorylation (Ser338) is a candidate for identifying ER-a þ patients at risk of relapse if treated with tamoxifen alone (McGlynn et al., 2009) . This hypothesis contradicts previous findings that increased expression of Raf-1 makes them more responsive to chemotherapeutic agents, such as paclitaxel in human breast cancer cells . To confirm this hypothesis, we investigated the pathological relevance of the relationship between Pin1, CDK10, Raf-1 and P-Raf-1 (338) in tamoxifen-resistant breast cancers. We found that CDK10 expression was decreased in TAMR-MCF7 cells and tamoxifen-resistant breast cancer cells, whereas Pin1 expression was increased. However, Pin1 silencing in TAMR-MCF7 cells increased the CDK10 level, indicating that Pin1 may induce CDK10 degradation through ubiqutination in breast cancer and cause tamoxifen resistance. In addition, our results showed that P-Raf-1 (Ser338), but not total Raf-1, was increased in TAMR-MCF7 cells and tamoxifen-resistant breast cancers. Recent study demonstrated that Pin1 regulates the phosphorylation status of Raf-1 kinase through regulation of the interaction with its phosphatase, PP2A (Dougherty et al., 2005) . In this study, the hyperphosphorylated/desensitized Raf-1 at Ser643 is subsequently dephosphorylated and returned to a signaling-competent state through interactions with the protein phosphatase PP2A and Pin1. Interestingly, our results showed that Pin1 silencing in TAMR-MCF7 cells decreased Raf-1 phosphorylation at Ser338 and CDK10 overexpression in TAMR-MCF7 cells decreased the Raf-1 phosphorylation. These results demonstrate that Pin1-induced-CDK10 ubiquitination may mediate the increased Raf-1 phosphorylation at Ser338, which caused tamoxifen resistance.
Sorafenib Nexavar) has demonstrated potent anti-tumor activity in preclinical models of breast cancer, lung cancer, colorectal cancer, renal cell carcinoma and hepatocellular carcinoma, all of which are known to exhibit a dysregulated Raf-1 pathway (Wilhelm et al., 2004; Yoshiji et al., 2004) . Recently, it was reported that breast cancer cells resistant to trastuzumab and lapatinib in HER-2 positive breast cancer can be efficiently inhibited by sorafenib (Valabrega et al., 2011) . Here, we showed that Raf-1 is activated in tamoxifen resistance breast cancer and the combined treatment of tamoxifen with sorafenib enhances the sensitivity of tamoxifen toward tamoxifen resistance breast cancers. In current studies, we identified a novel underlying mechanism for Pin1-induced CDK10 downregulation, namely, the phosphorylation of CDK10 at Thr133 to be primed and ubiquitinated by Pin1. In addition, CDK10 down-regulation is associated with Raf-1 phosphorylation and increased risk of relapse and death with tamoxifen treatment. On the basis of the above findings, we developed two strategies to sensitize breast cancer to tamoxifen, that is, either overexpression of CDK10 or inhibiting Raf-1 activity by sorafenib. The results showed that under treatment with the two methods, the TAMR-MCF7 was sensitized to tamoxifen. In conclusion, this newly identified mechanism provides a scientific basis for a plausible combination of chemodrugs in breast cancer, tamoxifen plus sorafenib, to overcome chemoresistance.
Materials and methods
Cell culture MCF7 cells, HEK293, and Pin1
þ / þ and Pin1 À/À MEF cells, kindly provided by Dr Kun Ping Lu (Beth Israel Deaconess Medical Center, Harvard Medical School), were maintained in DMEM with 10% FBS. SKBR-3 was maintained in McCoy's 5A with 10% FBS. To establish the TAMR-MCF7 cells, a stepwise drug selection was continued until the MCF7 cell population could sustain viability and proliferation when challenged with 3 mM of tamoxifen and the established TAMR-MCF7 cells were maintained in DMEM with 10% charcoal/ dextran-treated FBS and 3 mM of tamoxifen.
Antibodies and reagents
Antibodies against cyclin D1, phospho-Raf-1 (Ser338), phospho-MEK1/2, phospho-ERK1/2, MEK1/2 and ERK1/2 were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). Anti-Pin1, -CDK10 and -Raf-1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). AntiXpress and anti-GAL4 antibodies were obtained from Invitrogen (Carlsbad, CA, USA) and Abcam (Cambridge, MA, USA). Anti-phosphothreonine-proline (pThr-Pro) antibody was purchased from Millipore (Billerica, MA, USA). Calf intestinal alkaline phosphatase, 4-OHT, MG132 and cycloheximide were obtained from Sigma-Aldrich (St Louis, MO, USA).
Construction of mammalian expression and small interfering RNA The cDNAs of CDKs were amplified by PCR, and each was introduced into the pACT and pBIND two-hybrid system vector (Promega, Madison WI, USA). cDNAs encoding the T133A, T196A and T257A mutants of CDK10 were generated using the QuickChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and subcloned into the pBIND vector to produce the GAL4-tagged constructs, respectively. The cDNA of Pin1-WT, -WW and -PPIase, which were a gift from Dr Kun Ping Lu, were subcloned into the pcDNA4-Xpress (Invitrogen), pGEX-5X-1 (GE Healthcare Biosciences, Pittsburgh, PA, USA), MSCV vector (Clontech, Mountain View, CA, USA), or pBIND vector. pcDNA4-Xpress-Pin1-S16A were gifts from Dr Jeong-Hyun Shim (Chunbuk National University). Human Pin1 (accession number: NM_006221) and human CDK10 (accession number: NM_052988) were silenced by transfecting cells with the ON-TARGETplus siRNA SMART pool-specific doublestranded RNA oligonucleotides (Dharmacon, Chicago, IL, USA) using Lipofectamine 2000 (Invitrogen).
Protein immunoblotting and immunoprecipitation
For immunoblotting, cells grown to 70 to 80% confluence were harvested in RIPA lysis buffer, disrupted by sonication and centrifuged at 12 000 r.p.m. for 10 min. Protein samples were subjected to SDS-PAGE and immunoblotting. For immunoprecipitation, cells were harvested in immunoprecipitation buffer and lysed. Equal amounts of protein were subjected to immunoprecipitation followed by immunoblotting analysis.
Glutathione S-transferase (GST) pull-down assays For GST pull-down assays, cells were transfected with the indicated plasmid DNA. Whole-cell lysates were prepared 48 h after transfection and incubated with glutathione-sepharose beads (GE Healthcare) containing either GST-Pin1 or GST at 4 1C for 4 h. The precipitated proteins were separated by SDS-PAGE and expression was detected by immunoblotting.
RNA isolation and semi-quantitative RT-PCR
Total RNA was isolated from cells using the RNeasy Micro Kit (Qiagen, Valencia, CA, USA). Reverse transcription-PCR (RT-PCR) was performed using the AccessQuick RT-PCR system (Promega) on a Gradient Thermal Cycler (BioRad Lab., Hercules, CA, USA) using the following PCR primers: human CDK10 (sense, 5 0 -ATCAGCAGCTTGCGGGAGAT-CA-3 0 ; antisense, 5 0 -GATGCTGGTGGTCTGCGTGGT-3 0 ), human Pin1 (sense, 5 0 -AGCAGCAGTGGTGGCAAAAA-3 0 ; antisense, 5 0 -GGCCAGAGACTCAAAGTCCT-3 0 ), and bactin (Promega). All data were normalized to b-actin as an internal control according to the manufacturer's instructions.
M2H assay
Cells were co-transfected with pBIND-Pin1, pACT-CDKs, alone or in combination, along with pG5-luciferase in an equal molar ratio. The cells were disrupted with passive lysis buffer (Promega) at room temperature for 30 min by gentle shaking, and then firefly luciferase activity was measured. The relative luciferase activity was normalized to Renilla luciferase activity.
Tumor samples
Breast cancer patients selected for immunohistochemical staining consisted of two groups: tamoxifen-resistant group (four patients, age range: 42-72) and non-tamoxifen-resistant group (eight patients, age range: 47-58). The tamoxifenresistant group included mammary infiltrating duct carcinoma patients who had undergone mastectomy with adjuvant hormone therapy and subsequent bone metastasis, and the non-tamoxifen-resistant group included mammary infiltrating duct carcinoma patients who had undergone mastectomy with adjuvant hormone therapy and had no subsequent local recurrence or metastasis within 5 years.
Immunohistochemical staining
All tumors investigated in the study were tested for CDK10, Pin1, Raf-1 and phospho-Raf-1. Immunolocalization for each protein was performed using a Polink-2 HRP plus anti-rabbit DAB detection kit (Golden Bridge International, Inc., Mukilteo, WA, USA) according to the manufacturer's protocol. Slides were incubated for 1 h with anti-Pin1 antibody and overnight with anti-CDK10, anti-phospho-Raf-1, and Raf-1 antibody. Instead of the primary antibody, normal goat serum was used in the negative control. Distinct nuclear staining was considered positive immune reactivity.
MTT assay
To estimate cell viability, cells were seeded (1 Â 10 4 cells) into 96-well plates and treated with various concentrations of 4-OHT and/or sorafenib. After 72 h, 10 ml of the CellTiter-96 Cell Proliferation Assay solution (Promega) were added to each well and the cells were incubated for 4 h in a 37 1C, 5% CO 2 incubator. The absorbance was then measured at 570 nm.
Apoptosis analysis
Apoptosis was detected by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick-end labeling (TUNEL) with an in situ Cell Death detection Kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions. Briefly, cells were transfected with pBIND-GAL4-CDK10. After 48 h, the cells were starved, treated with 4-OHT for 24 h, stained with TUNEL solution, incubated at 37 1C for 2 h, washed with PBS, and mounted with crystal mount reagent for 4 h in the dark. The amount of DNA fragmentation was detected by using an Axiovert-200M fluorescence microscope (Carl Zeiss Inc., Thornwood, NY, USA).
Apoptosis assessed by flow cytometry The induction of apoptosis was analyzed by flow cytometry using the Becton Dickinson FACS Calibur Flow Cytometer (BD Biosciences, Sparks, MD, USA). TAMR-MCF7 cells were transfected with pBIND-CDK10, incubated for 48 h, starved for 24 h, and then treated with 4-OHT for 24 h. Apoptosis were detected using Annexin V-FITC and propidium iodide staining according to the manufacturer's protocol.
Anchorage-independent cell transformation assay Briefly, cells (8 Â 10 3 ) were exposed to different concentrations of 4-OHT in 1 ml of 0.3%. basal medium Eagle's agar containing 10% FBS. The cultures were maintained at 37 1C in a 5% CO 2 incubator for 10-15 days, and the cell colonies were scored using an Axiovert-200M florescence microscope.
Chorioallantoic membrane (CAM) assay Briefly, fertilized chicken eggs were transferred to an egg incubator and allowed to grow for 10 days. After TAMR-MCF7 cells (2 Â 10 6 ) were placed on the exposed CAM, the eggs were incubated in a humidified incubator at 37 1C for three days and treated with 4-OHT, sorafenib, or both. After 4 days, images were digitally recorded at Â 15 magnifications with an SZ-61 stereomicroscope (Olympus, Center Valley, PA, USA). The tumors were excised, fixed in 10% formalin and embedded in paraffin, and cell staining was performed with hematoxylin and eosin.
Statistical analysis
Fisher's Exact test with two-sided values of probability (P) was used to analyze the correlation between Pin1, CDK10, Raf-1 and phospho-Raf-1 in tamoxifen-resistant breast cancer patients. Data from cell viability, RT-PCR and soft agar assays were statistically analyzed using unpaired t-tests, and P-values o0.05 were considered significant.
